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Abstract
Background: Exercise during chemotherapy is a promising strategy to reduce fatigue and improve health-related
quality of life (HRQoL). It has been shown to be feasible and efficient in various cancers, including advanced-stage
cancers. Effects of physical activity have never been explored in advanced pancreatic ductal adenocarcinoma
(PDAC). We aim to evaluate the effects of an exercise intervention in this setting.
Methods: This randomized, national, multicenter, interventional study will examine the effectiveness of an
unsupervised, home-based, 16-week adapted physical activity (APA) program. Specificities of advanced PDAC for
the implementation of the APA program will be taken into account (healthy volunteer as physical activity partner
instead of patient groups, nutritional management). The main inclusion criteria are: patients with histologically
confirmed, unresectable PDAC; scheduled for chemotherapy; performance status 0–2; age ≥ 18; and physical activity
partner. In total, 200 patients will be randomized into either the APA program (aerobic and resistance exercises) in
addition to usual care (including chemotherapy at the investigator’s choice), or usual care. The primary objective
will be the effect on fatigue (Multidimensional Fatigue Inventory, MFI-20) and HRQoL (European Organization for
Research and Treatment of Cancer-Quality of Life-C30 questionnaire, EORTC-QLQ-C30; co-primary endpoint) at week
16. As secondary objectives, the effects of the exercise intervention on pain, anxiety, depression, nutritional status,
insulin resistance, tolerance of chemotherapy, survival, and adherence to the APA program will be evaluated.
Discussion: Patients with advanced PDAC are strongly affected by fatigue, and are thus likely to benefit from an
exercise intervention. Moreover, exercise may have a potential beneficial effect on tumor outcome by reducing
insulin resistance and insulin/insulin-like growth factor-1 (IGF-1) secretion. However, an exercise intervention may
appear challenging due to multiple PDAC-related symptoms such as fatigue, depression, pain, and denutrition. We
hypothesize that an APA program taking into account specific characteristics of PDAC may improve symptoms and
HRQoL. If demonstrated to be feasible and effective, such APA programs will be systematically proposed to patients
with advanced PDAC in addition to usual care.
Trial registration: ClinicalTrial.gov Registration number: NCT02184663; Registration date: 2 July 2014.
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Background
Current knowledge about physical activity in cancer
patients
Physical activity is associated with a decreased risk of
cancer, including colorectal, breast, and endometrial
cancers [1–4]. According to the World Health
Organization (WHO), 30 minutes of physical activity five
times per week may reduce the risk of developing colo-
rectal or breast cancer by about 25 %.
There is accumulating evidence that physical activity is
also beneficial for patients with cancer in reducing dis-
ease and/or treatment-induced symptoms (including
pain, fatigue, and anxiety/depression), and improving
health-related quality of life (HRQoL) as well as treat-
ment tolerance and adherence [5–8]. Fatigue in cancer
patients is multifactorial and can be related to the dis-
ease itself, treatment, and bed rest, leading to decondi-
tioning. Deconditioning, that is, loss of physical
(cardiorespiratory function and muscle strength) and
psychological fitness caused by reduced physical activity,
is one of the main causes of cancer-related fatigue [9].
Paradoxically, rest may have deleterious effects on these
patients, while physical exercise is the best way to re-
duce deconditioning and fatigue [10–12]. Several studies
have reported a 30 % reduction in cancer-related fatigue
and maintained cardiorespiratory fitness and muscle
strength with higher physical activity, even in advanced-
stage cancer [8].
A beneficial effect of physical activity on overall sur-
vival (OS) has also been reported in the most frequent
cancers such as those of the breast, colon, and prostate
[13]. Exercise reduces circulating estrogen and sex hor-
mone binding globulin (SHBG) levels in sex hormone-
dependent cancers, improves insulin profile (insulin-re-
lated pathways including insulin-like growth factor 1
[IGF-1]), reduces inflammation, and increases natural
killer and T-cell-mediated immunity [13–18]. Moreover,
physical activity may improve survival through its im-
pact on HRQoL, a prognostic indicator of survival in
various cancers including pancreatic cancer [19, 20].
The French National Cancer Institute (INCa) (http://
www.afsos.fr/) promotes physical activity in the preven-
tion and management of cancer at any time. The French
association for supportive care in cancer (Association
Francophone pour les Soins Oncologiques de Support,
AFSOS, http://www.afsos.fr/), the American College of
Sports Medicine (ACSM), and the American Cancer Soci-
ety (ACS) have edited guidelines for “adapted physical ac-
tivity” (APA) in cancer patients based on published data
[21–24]. In France, but also in many other countries,
adapted physical activity (APA) is a concept defined by the
International Federation of Adapted Physical Activity
(IFAPA) as “a cross-disciplinary body of practical and the-
oretical knowledge directed toward impairments, activity
limitations, and participation restrictions in physical activ-
ity. It is a service delivery profession and an academic field
of study that supports an attitude of acceptance of individ-
ual differences, advocates access to active lifestyles and
sport, and promotes innovative and cooperative service de-
livery, supports, and empowerment. Adapted physical ac-
tivity includes, but is not limited to, physical education,
sport, recreation, dance, creative arts, nutrition, medicine,
and rehabilitation.” [25]. In the cancer setting, the term
APA is used for exercise interventions involving profes-
sional trainers who have graduated with an academic de-
gree in APA. Implementation of an APA program in
patients with cancer implies a multidisciplinary collabor-
ation between the cancer-care medical team and APA pro-
fessionals. The APA program should be individualized
according to the patient (physical fitness, exercise type
preferences, psychological functions, and expectations),
the cancer (stage, treatments, and tolerance), and the so-
cial environment. A combined aerobic exercise and
resistance-training program is hypothesized to be the
most efficient way to improve physical fitness and de-
crease fatigue and therefore should be favored [21–24].
Patient adherence to the APA program is crucial for its ef-
ficacy. Performing exercise in groups of patients having
similar physical capabilities and under the supervision of
an APA professional whenever possible is the best way to
ensure patient motivation. The APA program also re-
quires the contribution of nutrition specialists (dietitians
or physicians) to balance energy intake with energy ex-
penditure. Little is known about the optimal duration of
exercise interventions, and no specific recommendation
from evidence-based guidelines exists [24]. In the
Cochrane meta-analysis review of randomized controlled
trials evaluating the effectiveness of exercise interventions
on health-related quality of life (HRQoL) in people with
cancer during active treatment [7], the length of exercise
intervention varied greatly between trials (3–26 weeks),
with a modal duration of 12 weeks. Similarly, a modal dur-
ation of exercise interventions of 12 weeks was reported
in the Cochrane meta-analysis of trials that investigated
the effect of exercise on the management of cancer-
related fatigue [8]. In patients who exercised during treat-
ment, improvements in global health and physical and
emotional functioning compared to baseline values were
found at week 12 [24]. Noticeably, in these studies, pa-
tients were allowed to continue exercise after the end of
the intervention period.
Epidemiology and management of pancreatic ductal
adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is the second
cancer of the digestive tract in incidence and one of the
poorest prognostic tumors with a 5-year survival rate of
less than 5 % [26]. More than 80 % of patients have an
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advanced, unresectable disease at diagnosis. Therapeutic
options remain limited in this setting [27]. Treatment
consists mainly of chemotherapy with weekly (gemcita-
bine or gemcitabine plus nab-paclitaxel regimens) or bi-
weekly regimens (fixed-dose rate [FDR] gemcitabine, the
combinations of 5-fluorouracil, irinotecan, and oxalipla-
tin [FOLFIRINOX], or gemcitabine and oxaliplatin
[GEMOX]). Radiation therapy is limited to selected pa-
tients with non-metastatic disease. To date, there are no
data about the role of APA in patients treated for an ad-
vanced PDAC.
Hypothesis for beneficial effects of exercise intervention
in patients with advanced PDAC
Fatigue is a common disease-related symptom in pa-
tients with advanced PDAC that contributes to impaired
HRQoL [28, 29]. We hypothesize that physical exercise
may limit physical deconditioning and reduce fatigue in
these patients. Physical activity may have a beneficial ef-
fect on pain, anxiety, and depression, symptoms affecting
more than half of PDAC patients, and may result in a
global improvement of HRQoL and in delayed deterior-
ation of HRQoL [30]. Moreover, an improvement in
HRQoL may translate into a survival benefit [20].
There is consistent evidence on the relationship be-
tween insulin resistance, insulin and IGF-1 secretions,
and pancreatic carcinogenesis [31–37]:
– Obesity and type II diabetes (metabolic syndrome)
are risk factors for PDAC (relative risk [RR] = 1.2–1.6
and 1.8–2.0, respectively) and physical activity may
have a protective effect (RR = 0.72),
– Metformin, a drug that decreases insulin resistance,
reduces the risk of developing PDAC in in vivo
preclinical studies and in observational clinical
studies of patients with type II diabetes,
– Insulin receptor is overexpressed in PDAC, and
insulin and IGF-1 stimulate proliferation of PDAC
cells in vitro,
– Some polymorphisms of IGF, IGF receptor, and
IGF-binding protein are associated with an increased
risk of PDAC and shorter survival in PDAC patients,
– Weight loss, impaired glucose tolerance and
diabetes, along with peripheral insulin resistance are
frequently observed in PDAC patients.
Physical exercise has been associated with reduced
insulin resistance and insulin and IGF-1 secretions
[13]. In addition, PDAC usually causes an intense in-
flammatory reaction that contributes to tumor-related
cachexia [38]. Exercise can modulate this process and
may have a beneficial effect on disease outcome (pro-
gression-free survival [PFS] and OS) in patients with
advanced PDAC.
Specificities of advanced PDAC affecting the
implementation of the APA program
Sessions in groups are suitable to maintain patient mo-
tivation, particularly in an adjuvant setting (for example,
for breast and colon cancer). In women with breast can-
cer, being part of a supportive social environment is ac-
knowledged in motivational and behavioral theories as a
key factor to health behavior change and stands among
the strongest incentives for exercise motivation [39].
However, we believe that patients with advanced PDAC
are not suitable for group sessions. These patients have
a poor prognosis and can deteriorate during the exercise
intervention period. Therefore, regular meetings of pa-
tients treated for PDAC may lead to negative and coun-
terproductive psychological impact on the group. For
this reason, we propose to include a “physical activity
partner,” a healthy volunteer, chosen by the patient, to
attend the exercise sessions. This practice is expected to
sustain the patient motivation and to be beneficial for
the partner in terms of psychological outcome, while
avoiding the potentially deleterious psychological effects
of the patient group [40]. Such organization will imply a
psychological evaluation of the partner to verify that he/
she is not experiencing psychological burnout.
Patients with PDAC often suffer from weight loss due
to an inadequate dietary intake combined with increased
energy expenditure [41]. Denutrition is experienced by
70–80 % of PDAC patients and is multifactorial in origin
including inflammatory and hypercatabolic syndrome,
stenosis of the digestive tract, cholestasis, exocrine pan-
creatic insufficiency, diabetes, anxiety, depression, and
chemotherapy adverse effects (nausea/vomiting, mucitis,
diarrhea, and loss of appetite). Patients with PDAC ap-
peared to have a significantly increased basal resting en-
ergy expenditure (REE) and spontaneously reduced
physical activity level compared with healthy individuals
[41]. As the APA program is expected to increase energy
expenditures, nutritional management will be crucial for
monitoring and adapting food intakes to ensure that pa-
tients meet their nutritional needs.
There is consistent evidence that a 12-week interven-
tion is the minimal duration of exercise intervention to
improve HRQoL and fatigue in patients with cancer [7,
8, 24]. In the setting of pancreatic ductal adenocarcin-
oma (PDAC), median progression-free survival (PFS) in
patients with metastatic disease ranges from 3 to 4
months with gemcitabine, from 5 to 6 months with gem-
citabine plus nab-paclitaxel or the FOLFIRINOX com-
bination regimens, and from 9 to 10 months in patients
with locally advanced PDAC [42–44]. Deterioration of
HRQoL is closely related to disease progression and sur-
vival, and can be affected by a change in chemotherapy
regimen in the case of tumor progression [20]. Thus,
evaluation of HRQoL can be biased in many ways by
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disease progression. Therefore, we propose a 16-week
intervention and HRQoL and fatigue data evaluation at
week 16, since most patients are expected to remain free
of disease progression during this time period and to re-
main on the same chemotherapy regimen. In addition,
evaluation of tumor status under treatment in advanced
PDAC is usually performed every 8 weeks; thus, this
length of exercise intervention was judged as well suited
for the timing of tumor evaluation.
Methods/design
Study objectives and hypotheses
The APACaP (Activité Physique Adaptée et chez des pa-
tients ayant un Cancer du Pancréas non résécable;
adapted physical activity in patients with unresectable
pancreatic adenocarcinoma) study aims to assess the ef-
ficacy of an unsupervised 16-week APA program on
physical fatigue (Multidimensional Fatigue Inventory,
MFI-20) and targeted dimensions of HRQoL (global
QoL, fatigue, physical functioning, and pain; European
Organization for Research and Treatment of Cancer-
Quality of Life-C30 questionnaire, EORTC-QLQ-C30),
unified as the co-primary endpoint (single sufficient de-
sign) at the end of the intervention in advanced PDAC
patients. Secondary objectives include assessing the
beneficial effects on pain, other HRQoL dimensions, de-
pression, nutritional status, insulin resistance, cancer-
treatment tolerance, PFS, and OS.
Design
The APACaP study is designed as a national, prospect-
ive, multicenter, randomized, controlled trial to test the
efficacy of an APA program, in which patients will be al-
located either to the intervention group invited to per-
form exercise in addition to usual care, or to the usual
care control group (Fig. 1). Because blinding of partici-
pants toward allocation is not feasible, this study will
have an open-label design.
Patients
Patients with histologically confirmed, previously un-
treated, unresectable (locally advanced or metastatic)
PDAC who meet the following criteria will be eligible
for the APACaP study: scheduled for chemotherapy;
Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS) ≤ 2 (Additional file 1: Table S1); age ≥ 18
years; at least one bi-dimensionally measurable lesion ac-
cording to the Response Evaluation Criteria In Solid Tu-
mors (RECIST) v1.1 criteria [45]; designated physical
activity partner; signed and dated informed consent; and
registration in a national health care system (CMU in-
cluded). Patients will be excluded if their cardiovascular,
respiratory, psychiatric, musculoskeletal, or neurological
condition contraindicates exercise practice. Participants
of other clinical studies will be eligible for the APACaP
study if the primary endpoints of both studies do not
overlap.
Ethics and regulatory considerations
Written informed consent will be obtained from all pa-
tients. The current study is to be conducted in accord-
ance with globally accepted standards of Good Clinical
Practice (ICH-E6), European Directive 2001/20/EC,
and the revised version of the Declaration of Helsinki
set out in the European Directive, as well as with the
Code de Santé Publique specific to France. The proto-
col has been submitted for formal approval of the study
conduct to ensure that the study meets the local regula-
tions to the Health Authorities, that is, the Agence
Nationale de Sécurité du Médicament et des produits
de santé (ANSM), and to a properly constituted Ethics
Committee. The study was approved by Health Author-
ities (ANSM), and full ethical approval was obtained
from a unique Ethics Committee for all centers in-
volved (CPP Ile-de-France VI N 32–14; ID RCB: 2014-
A00228-39), in compliance with French regulations.
The study has been registered on ClinicalTrial.gov
(NCT).
Fig. 1 The APACaP study design. CT: chemotherapy
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Recruitment and randomization
This study is promoted by the Groupe Coopérateur
Multidisciplinaire en Oncologie (GERCOR) and will be
conducted in 16 centers in France (managed by the
GERCOR and Partenariat de Recherche en Oncologie
DIGEstive [PRODIGE] cooperative groups). Newly diag-
nosed patients with advanced PDAC identified as eligible
will be informed about the program and invited to par-
ticipate in the study during a regular outpatient visit.
The clinician will assess the patient eligibility and will
provide each patient and/or a legal representative with
relevant, comprehensive, verbal and written information
regarding the objectives and procedures of the study as
well as their possible risks. The patient will be given a 1-
week reflection period (up until the first chemotherapy
cycle) in order to inquire about study details. All ques-
tions raised by the patient should be answered in a satis-
fying manner. The investigator will inform each patient
about his/her right to withdraw from the study at any
time for any reason. A signed informed consent will be
obtained from each patient and/or legal representative
prior to undertaking any study-related procedure.
Eligible patients will be randomized in a 1:1 ratio by a
central computer-assisted procedure centralized at the
GERCOR data center. Randomization will be performed
using a minimization technique and will be stratified per
center, cancer stage (locally advanced versus metastatic),
chemotherapy schedule (weekly versus biweekly regi-
men), ECOG PS (0–1 versus 2), and baseline physical ac-
tivity level (low, moderate, or intense according to the
Global Physical Activity Questionnaire [GPAQ]). Each




Participants assigned to the control group will receive
usual care (that is, with no physical activity intervention)
including chemotherapy at the investigators’ choice
(according to the patient general condition and biol-
ogy, comorbidity, and tumor stage: weekly gemcitabine
or gemcitabine plus nab-paclitaxel regimens; biweekly
FDR gemcitabine, FOLFIRINOX, or GEMOX), out-
patient clinical visits according to the regular schedule,
nutritional support according to the national recom-
mendations (Société Francophone de Nutrition Clini-
que et Métabolisme [SFNEP]), and tumor evaluation
based on carbohydrate antigen 19–9 (CA 19–9) serum
levels and thoraco-abdominopelvic computed tomog-
raphy (TAP-CT) every 8 weeks.
Intervention group
Participants assigned to the intervention group will
receive usual care plus a 16-week APA program.
The APA program, designed according to the AFSOS
recommendations, will be directed by an APA profes-
sional trainer selected from a list of certified profes-
sionals chosen for the study. Exercise sessions will be
implemented in addition to daily life activities. The exer-
cise training program will consist of one supervised
demonstration session with the APA professional, and
thereafter the training will be continued as unsupervised,
home-based exercise training sessions.
Two types of exercises will be proposed: 1) aerobic ex-
ercises including walking, and/or Nordic walking, and/or
cycling, according to patient preference and 2) resistance
exercises using elastic bands to maintain or increase arm
and leg muscle strength.
Duration, frequency, and intensity of exercises will be
adapted for each patient by the APA professional ac-
cording to standardized guidelines. Patient fitness before
treatment (estimated by the GPAQ), deconditioning
level, and baseline physical evaluation (6-minute walking
test and maximal strength test) will be considered. The
APA professional will define exercise intensity based on
baseline patient physical evaluation. Aerobic exercises
will be performed with an intensity that will allow the
patient to speak comfortably. The muscle-strengthening
program will consist of repetitions performed at 50 % of
baseline maximal strength test. One-repetition max-
imum (1-RM) is a measure of muscular strength; it is
the highest weight that can be lifted for one repetition
and one repetition only. Elastic bands (TheraBands®),
available as the eight color-coded resistance level bands,
are frequently used to assess the 1-RM [46, 47]. The
APA professional will measure the distance from starting
position to ending position during exercise with the elas-
tic band to determine its deformation. After a warm-up
without the elastic band and based on the APA profes-
sional assumption of the patient’s approximate strength,
the appropriate band will be chosen for exercise. If the
patient can perform more than ten repetitions with good
form, a higher resistance band will be tested. The
amount of deformation, the elastic band color, and the
number of repetitions are required parameters to calcu-
late a 1-RM. The 1-RM test is calculated based on the
Brzycki equation: 1-RM = weight loaded/ (1,0278 -
(0,0278 x number of repetitions)) [48]. The weight
loaded is defined for each color of elastic bands de-
pending on the level of deformation [49].
Physical activity sessions will comprise exercises for
warming up followed by aerobic or resistance exercises
and a recuperation period. The warming-up and recu-
peration periods will account for at least 30 % of the ses-
sion duration. The aim of the APA program is to
gradually reach a total of 30 minutes of aerobic training,
three to five times per week (according to physical con-
dition), and to perform strengthening activities at least
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two times per week for all the major muscle groups, ex-
cluding the warming-up and recuperation periods. A
lower intensity activity week will be planned every 4
weeks to prevent patient exhaustion.
Patients will be asked to report on their APA program
in a dedicated activity booklet. Photographs and explana-
tions for good positioning and proper execution of exer-
cises will be provided to patients. The APA professional
will monitor weekly the program tolerance and adherence
during a video call (a webcam will be provided to the
patient if necessary). The booklet can be used to help
patients recall exercises performed and difficulties en-
countered. The video call will allow the APA profes-
sional to evaluate leisure activities, sessions of aerobic
training, and strengthening exercises, and to assess
the patient tolerance and difficulties in completing
the physical activity level. Depending on this evalu-
ation, the APA program will be adapted according to
the scheme illustrated by Fig. 2. Difficulty of activities
will be increased in duration, then in frequency, and
ultimately in intensity. Exercise intensity will be en-
hanced only if the patient tolerates an increase in
duration and frequency.
A supervised session with elastics can be performed
during video call on patient demand.
After completion of the 16-week study program, the
patient will be offered the option of pursuing the phys-
ical exercises.
The APA program will be temporary interrupted in
the following cases: uncontrolled infection, thrombo-
embolic event (first 7 days of anticoagulant therapy), un-
controlled pain, symptomatic anemia or hemoglobin
level < 10 g/dl, platelet counts < 50,000/mm3, and a
major surgery.
Termination of the patient participation in the study
can occur in the following situations: on patient’s re-
quest, deterioration of general condition with ECOG
PS > 2, uncontrolled symptoms, clinical problem defini-
tively contraindicating exercise practice, clinicians’ or
trainers’ decision in the best interest of the patient, ser-
ious adverse event (AE) resulting from physical exercise
or preventing the patient from pursuing exercise, loss to
follow-up, and major protocol deviation.
The patient will be asked to designate a physical activ-
ity partner (a healthy family member/relative or friend)
who can attend (without obligation of performing exer-
cises) and support the patient for at least one exercise
session per week. The physical activity partner will be
given all needed information and will be allowed to at-
tend the patient visits with the physical activity trainer.
Psychological follow-up of the physical activity partner
will be scheduled using the Hospital Anxiety and
Depression Scale (HADS).
The APA program will be associated with a nutritional
intervention supervised by a dietitian. Nutritional man-
agement will be designed according to the SFNEP
Fig. 2 Mapping of the progression steps of the 16-week adapted physical activity (APA) program
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recommendations. Practically, patient nutritional status
will be assessed based on clinical (actual weight, weight
loss, and body mass index) and biological (albumin, pre-
albumin, and C-reactive protein [CRP]) parameters. The
daily calorie and protein requirements will be calculated
using the Harris-Benedict equation for patient basal en-
ergy expenditures. To determinate the total daily caloric
requirements, two variables, the individual cancer-
related stress factor (REE x 1.3) and the activity factor
(REE x 1.4 a 1.6) will be considered. A three-day food
intake evaluation will be performed. Nutritional inter-
vention (oral feeding and enteral and/or parenteral
nutrition) will be decided according to the SNFEP
guidelines.
Safety
All AEs reported by the patient or observed by the clin-
ician and the APA professional (sports accidents, ex-
haustion, or injuries) will be recorded. All serious AEs
will be reported to the ANSM and to the accredited
European Commission that approved the study protocol.
It will be the responsibility of the clinician investigator
to record all the relevant information regarding any
event occurring during the APA program. The investiga-
tor will be requested to assess the relationship between
the intervention and the occurrence of each AE using
clinical criteria. Alternative causes such as natural his-
tory of the underlying diseases, concomitant therapy,
other risk factors, and the temporal relationship of an
event to the intervention will be considered and
investigated.
The investigators and all other appropriate persons
will be informed of findings that could adversely affect
the safety of patients in a timely manner during the
study duration.
Study endpoints and measures
Primary outcome
The primary outcome of the APACaP study is to assess
the effects of the APA program on fatigue (one targeted
dimension) and HRQoL (four targeted dimensions), uni-
fied as a co-primary endpoint, at the end of a 16-week
intervention in patients with advanced PDAC. We
hypothesize that exercise intervention will significantly
improve at least one of these five parameters without
significantly deteriorating the others.
Fatigue will be measured using the validated French
version of the MFI-20 questionnaire [50, 51]. The MFI-
20 is a 20-item self-reported instrument, organized into
five scales: general, physical, mental fatigue, and reduced
activity and motivation, and is designed to assess mul-
tiple fatigue dimensions. The targeted dimension will be
the physical fatigue scale. A change of two or more units
will be considered as a clinically relevant change [52].
The EORTC-QLQ-C30 questionnaire comprising five
functional scales (physical, role, emotional, cognitive,
and social), one global QoL scale, and a 10-item symp-
tom scale (including fatigue and pain) will be used to
measure HRQoL [53]. The four targeted dimensions will
be global QoL, fatigue, physical functioning, and pain. A
change of five or more units will be considered as the
minimal clinically important change [54].
Secondary outcomes
Secondary outcomes will consist in the longitudinal ana-
lysis of fatigue and HRQoL, and the effects on pain, de-
pression, nutritional status, insulin resistance, cancer-
treatment tolerance, and survival.
Longitudinal analysis of fatigue and HRQoL will be
performed using a linear mixed-effects regression model
(repeated measures analysis of variance [ANOVA]) to
test randomization and time effects and a time-
treatment interaction. In case of non-random missing
data, pattern mixture models will be used. Time until
definitive deterioration (TUDD) of targeted scores will
be defined as the interval between the measurement of
HRQoL at baseline (before randomization) and the date
of occurrence of a 5-point or greater HRQoL score de-
terioration, no improvement thereafter, or death from all
causes [20, 55, 56]. If deterioration is not observed, pa-
tients will be censored at the last date at which the pa-
tient has filled out the questionnaire.
Pain will be assessed using a visual analogue scale
(VAS), analgesics consumption, and the French validated
version of the Brief Pain Inventory-Short Form (BPI-SF)
questionnaire [57, 58]. The BPI-SF questionnaire is a 15-
item scale evaluating five parameters of pain: severity,
impact on daily function, location, pain medications, and
amount of pain relief in the past 24 hours or the past
week. Two scores will be calculated to assess the severity
of pain and the impact of pain on daily functions.
Anxiety and depression will be rated using the French
validated version of the HADS questionnaire and based
on anxiolytic and antidepressant consumption [59, 60].
The HADS questionnaire evaluates emotional state re-
ported by the patient during the week before the assess-
ment date. It consists of 14 items including seven for
anxiety and seven for depression. Each item is rated on a
0–3 rating scale (3 = highest intensity level of feeling).
The anxiety and depression scores will be calculated by
the sum of the corresponding seven items. A score > 11
will be considered as significant for the presence of an
anxiety or depression problem.
Nutritional status will be evaluated based on weight,
body mass index (kg/m2), body composition (bioimpe-
dancemetry method in equipped centers), food intake
(assessed using a VAS), and biological parameters (albu-
min, prealbumin, and CRP).
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Insulin resistance will be determined based on levels
of fasting plasma glucose, insulin, hemoglobin A1c
(HbA1c hemoglobin), plasma IGF-1, insulin and antidia-
betic agent requirements, and homeostasis model assess-
ment (HOMA).
Tolerability of chemotherapy will be assessed in terms
of toxicities or treatment delay. Toxicities will be graded
using the Common Terminology Criteria for Adverse
Events (CTCAE) v 4.0.
Effects on PFS and OS will be analyzed. PFS is defined
as the time elapsed from treatment initiation to first
tumor progression (according to the RECIST v1.1 cri-
teria), or death from any cause; censored are patients
alive or lost to follow-up [45, 56]. OS is defined as the
time elapsed from treatment initiation to death from any
cause, or last follow-up.
Exercise tolerance will be monitored using the booklet,
visual scales (dyspnea, muscular pain), and a Borg scale.
The effects of physical activity on deconditioning, car-
diorespiratory function, and muscle strength will be
evaluated using the International Physical Activity Ques-
tionnaire (IPAQ), the resting heart rate and blood pres-
sure, a 6-minute walking test with monitoring of the
heart rate during exertion, a maximal strength test with
elastic bands, and bioimpedancemetry. Adherence to the
APA program will be registered in the patient booklet
and during video calls.
Data will be collected for the 24-month follow-up period
after enrollment. Tables 1 and 2 provide a summary of the
study activities, measures, and schedule of visits.
Sample size
To detect a difference between the two groups at a global
type I error of 5 %: 1) a change of five units (standard de-
viation [SD] = 10) for at least one of the EORTC-QLQ-
C30 targeted dimensions (global QoL, fatigue, physical
functioning, and pain) with an alpha error risk of 1 %
in a bilateral design (with a Bonferroni adjustment
of 4 %/4 = 1 %) and a statistical power of 80 % with a
mean comparison test, a total of 190 patients are re-
quired [54]; 2) or a change of two units (SD = 4) for
the targeted dimension of the MFI-20 scale (physical
fatigue), with an alpha error risk of 1 % in a bilateral
design (with a Bonferroni adjustment of 1 %) and a
power of 80 % with a mean comparison test, a total
of 190 patients are required [52].
The effects of exercise on fatigue and HRQoL will be
tested after 16 weeks, 6 months, and 24 months post-
enrollment. An interim analysis will be performed after
half of the patients have achieved at least 6 months of
follow-up using the O’Brien-Fleming method (to reject
the null hypothesis [H0; efficacy] or to reject the study
hypothesis [H1; futility]). All analysis will be performed
using EAST software v5.
An arm will be considered superior to the other arm if
at least one of the targeted dimensions of the EORTC-
QLQ-C30 is significantly superior without any targeted
dimension being superior in the other arm. Otherwise,
at least three out of the five targeted dimensions will be
required to be significantly superior in order to consider
that one of the study arms is globally superior to another
arm.
To anticipate a dropout of 5 % (that is, discontinuation
of participation and loss to follow-up), a total of 200 pa-
tients will be randomized. In order to show that median
TUDD for one of the targeted dimensions of the
EORTC-QLQ-C30 shows change from 5 months to 8.5
months (HR = 0.58) with an alpha error risk of 1 % in a bi-
lateral design (with a Bonferroni adjustment of 5 %/5 = 1 %)
and a power of 80 %, a total of 200 patients with a min-
imal 12-month follow-up will be required to observe 170
events [20].
Data analysis
Descriptive statistics will be used to characterize the
study population and the instrument scores at baseline
and at follow-up. Statistical analyses will be performed
with SAS v9.2, Stata v12, or R v2.15. All primary statis-
tical analyses will be conducted on the intention-to-treat
population. A P value of < 0.01 and of < 0.05 will be con-
sidered statistically significant for the primary endpoint
and secondary endpoints, respectively. Results will be
presented for the total study population and according
to center, cancer stage, chemotherapy schedule, ECOG
PS, and baseline physical activity level.
The study data analysis will be conducted according to
the following steps:
1. Description of the study sample Patient characteris-
tics will be described for all the demographic and clinical
data recorded at inclusion. Qualitative variables will be
presented using absolute numbers and percentages, to-
gether with their 95 % confidence intervals (CI). Quanti-
tative variables will be reported using mean (±SD) or
median (min/max). Interaction tests will be performed.
The comparison of means will be carried out using Stu-
dent’s t-test, the Wilcoxon rank-sum test, analysis of
variance (ANOVA), and the Kruskall-Wallis test, as ap-
propriate. The association of qualitative variables will be
carried out using chi-square or Fisher’s exact tests, as
appropriate.
2. Score calculation and management of missing data
Questionnaire scores will be calculated according to the
authors’ recommendations. Patients with missing data
will be excluded from analysis. If data are missing at ran-
dom, the average of items answered in the dimension
will be measured, and if data are not missing at random,
a multiple imputation method will be used to complete
the dataset.
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Table 1 Schedule of visits and measures in the control arm
Screening visit Randomization visit Study visit End of treatment Follow-up visit




Physical activity partner X
Physical activity level GPAQ X
Demographic and clinical data X
Concomitant treatment X X X X X X X X X X X X X X X X X X X X X
Pathological data X
Clinician visit X X X X X X X X X X X X X X
Physical exam X X X X X X X X X X X X X X X X X X X X X
ECG X
Questionnaires X X X X X X X X X X X X X X
6-minute walking test X X X X X X X
Maximal strength test X X X X X X X
Body composition X X X X X X X
Physical activity level IPAQ X X X X X X X
Biology tests
Type 1 X X X X X X X
Type 2 X X X X X X X X X X X X
Type 3 X X
Biobank (optional) X
TAP-CT X Xa X X X X X X X X X X X
CA-19.9 X Xa X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X X X X X X
CA 19–9 carbohydrate antigen 19–9, CRP C-reactive protein, GPAQ Global Physical Activity Questionnaire, HbA1c glycated hemoglobin, HOMA homeostasis model assessment, IGF-1 insulin-like growth factor 1, IPAQ
International Physical Activity Questionnaire, TAP-CT thoraco-abdominopelvic computed tomography
aA +/− 2-week time interval is considered as acceptable
Biology tests - type 1: blood cell count, CRP, fasting glucose, HbA1c, insulin/HOMA, IGF-1, albumin, prealbumin
Biology tests - type 2: blood cell count, CRP, fasting glucose, albumin, prealbumin
Biology tests - type 3: blood cell count, CRP, fasting glucose, insulin/HOMA, IGF-1, albumin, prealbumin










Table 2 Schedule of visits and measures in the intervention arm
Screening visit Randomization visit Study visit End of treatment Follow-up visit




Physical activity partner X
Physical activity level GPAQ X
Demographic and clinical data X
Concomitant treatment X X X X X X X X X X X X X X X X X X X X X
Pathological data X
Clinician visit X X X X X X X X X X X X X X X
APA professional X X (X) (X) (X) (X)
Dietitian X X X X X X (X) (X) (X) (X)
Physical exam X X X X X X X X X X X X X X X X X X X X X
ECG X
Questionnaires X X X X X X X X X X X X X X
6-minute walking test X X X X X X X
Maximal strength test X X X X X X X
Body composition X X X X X X X
Physical activity level IPAQ X X X X X X X
Biology tests
Type 1 X X X X X X X
Type 2 X X X X X X X X X X X X
Type 3 X X
Biobank (optional) X
TAP-CT X Xa X X X X X X X X X X X
CA-19.9 X Xa X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X X X X X X
CA 19–9 carbohydrate antigen 19–9, CRP C-reactive protein, GPAQ Global Physical Activity Questionnaire, HbA1c glycated hemoglobin, HOMA homeostasis model assessment, IGF-1 insulin-like growth factor 1, IPAQ
International Physical Activity Questionnaire, TAP-CT thoraco-abdominopelvic computed tomography
aA 2-week time (+/−) interval is considered as acceptable
(X): only for patients pursuing the APA program after week 16
Biology tests - type 1: blood cell count, CRP, fasting glucose, HbA1c, insulin/HOMA, IGF-1, albumin, prealbumin
Biology tests - type 2: blood cell count, CRP, fasting glucose, albumin, prealbumin










3. Statistical analysis of the primary endpoint Absolute
(mean [SD] and median [min/max]) scores for fatigue
and HRQoL at inclusion and at each time point will be
measured and compared between the two groups. An
ANOVA will be carried out after determining the nor-
mality of the distribution of the scores. Univariate ana-
lyses of variance will be performed to compare the
targeted dimensions at week 16 between the two groups,
to calculate the average of the difference, and to identify
potential confounders in the relationship between the
exercise intervention, fatigue, and HRQoL. Factors with
a statistical threshold of 5 % will be integrated into a
multivariate ANOVA. The results will be presented with
99 % CI.
4. Statistical analysis of secondary endpoints TUDD
scores for fatigue, targeted HRQoL dimensions, OS, and
PFS will be estimated by the Kaplan-Meier method and
compared using a log-rank test. The effect of the inter-
vention will be expressed as hazard ratio (HR) with a 99
% CI. The Cox regression model will be used for multi-
variate analysis to measure the effect of the intervention
on the five targeted dimensions. Different definitions of
TUDD and types of events will be investigated in sensi-
tivity analyses [20]. For the analysis of anxiety/depres-
sion and pain data, the variance analysis models will be
used to assess whether, compared to baseline measure-
ments, patients show changes in scores following the in-
terventions (at each time point). Continuous data will be
checked for normal distribution and, where applicable,
log transformation will be applied to the data. The intra-
class correlation coefficients for outcome variables of
interest will be calculated. Univariate and multivariate
logistic regression analyses of grade 3–4 toxicities and
3–4 late complications will be performed. Weight and
BMI variables, as well as physical activity level and nutri-
tional status variables, will be compared between groups.
The HADS questionnaire will be completed by the phys-
ical activity partner and analyzed for descriptive purposes.
Discussion
Fatigue and altered HRQoL are common symptoms in
patients with cancer receiving chemotherapy. Adapted
physical activity during treatment is an original and
promising non-pharmaceutical strategy that may help
better manage these symptoms in supportive and pallia-
tive care interventions. Previous data have indicated that
APA is feasible and efficient in various cancers. Effects
of an exercise intervention in patients with advanced
PDAC have never been explored. As these patients are
strongly affected by fatigue, we hypothesized that they
are likely to benefit from the exercise intervention. In
addition, exercise has been reported to have a beneficial
effect on tumor outcomes by reducing insulin resistance
and insulin and IGF-1 secretion.
In this study, characteristics of patients with advanced
PDAC that may affect the implementation of the APA
program were taken into account. We propose an ori-
ginal method: the introduction of the physical activity
partner to optimize patient adherence. This approach is
based on the hypothesis that patient group sessions may
be psychologically counterproductive in advanced PDAC
patients because of the likely risk of short-term degrad-
ation of PS in several participants. Moreover, given that
nutrition is a critical issue in the management of pa-
tients with PDAC and that physical exercise may in-
crease patient denutrition by increasing energy
expenditures, we carefully adapted a nutritional inter-
vention to the APA program.
In conclusion, the APACaP study is a large multicenter
randomized controlled trial to assess the feasibility and
the efficacy of an unsupervised 16-week APA program
on fatigue and HRQoL in patients with advanced PDAC.
This intervention may appear challenging in those pa-
tients, given multiple cancer-related symptoms (fa-
tigue, depression, pain, and denutrition). However, we
hypothesize that the APA program may be beneficial
for patients with advanced PDAC and may improve
PDAC-related symptoms and HRQoL. If the APA pro-
gram proves to be feasible and effective in this popula-
tion, systematic implementation of this approach in
association with anti-tumoral treatment will be the
next logical step in this setting. Finally, the study re-
sults may also have implications for the multimodal
treatment of other digestive cancers.
Trial status
APACaP started enrolling patients in September 2014.
Study is ongoing, and the completion date is estimated
at December 2017.
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